The U.S. Food and Drug Administration (FDA) on Saturday authorized Johnson & Johnson’s COVID-19 vaccine for emergency use in the United States. It does not have to be kept in extra-cold facilities, and is a one dose vaccine.
It is the third COVID-19 vaccine that has received FDA’s emergency use authorization (EUA) in the country, following the first one developed by American drugmaker Pfizer in partnership with German company BioNTech, and second one developed by American drugmaker Moderna.
Results from a trial of about 44,000 participants show the J&J vaccine was 66% effective in preventing moderate-to-severe COVID-19 globally.
A review of available data by an independent safety monitoring board indicated that a single-dose of the COVID-19 vaccine was generally well-tolerated.